ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis

NASDAQ:ADMA • US0008991046

15.57 USD
+0.39 (+2.57%)
At close: Feb 27, 2026
15.28 USD
-0.29 (-1.86%)
After Hours: 2/27/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ADMA. ADMA was compared to 520 industry peers in the Biotechnology industry. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability. ADMA has a bad growth rate and is valued cheaply. These ratings could make ADMA a good candidate for value investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year ADMA was profitable.
  • ADMA had a positive operating cash flow in the past year.
  • ADMA had negative earnings in 4 of the past 5 years.
  • In multiple years ADMA reported negative operating cash flow during the last 5 years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 36.83%, ADMA belongs to the top of the industry, outperforming 98.85% of the companies in the same industry.
  • The Return On Equity of ADMA (48.57%) is better than 98.66% of its industry peers.
  • ADMA's Return On Invested Capital of 25.76% is amongst the best of the industry. ADMA outperforms 98.85% of its industry peers.
Industry RankSector Rank
ROA 36.83%
ROE 48.57%
ROIC 25.76%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • ADMA has a better Profit Margin (42.87%) than 98.28% of its industry peers.
  • With an excellent Operating Margin value of 34.19%, ADMA belongs to the best of the industry, outperforming 96.93% of the companies in the same industry.
  • The Gross Margin of ADMA (54.71%) is better than 76.82% of its industry peers.
  • In the last couple of years the Gross Margin of ADMA has grown nicely.
Industry RankSector Rank
OM 34.19%
PM (TTM) 42.87%
GM 54.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • There is no outstanding debt for ADMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • ADMA has an Altman-Z score of 18.21. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ADMA (18.21) is better than 88.31% of its industry peers.
  • The Debt to FCF ratio of ADMA is 1.78, which is an excellent value as it means it would take ADMA, only 1.78 years of fcf income to pay off all of its debts.
  • ADMA has a Debt to FCF ratio of 1.78. This is amongst the best in the industry. ADMA outperforms 93.68% of its industry peers.
  • A Debt/Equity ratio of 0.16 indicates that ADMA is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.16, ADMA is doing worse than 63.98% of the companies in the same industry.
  • Even though the debt/equity ratio score it not favorable for ADMA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.78
Altman-Z 18.21
ROIC/WACC3
WACC8.6%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • ADMA has a Current Ratio of 7.13. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 7.13, ADMA is doing good in the industry, outperforming 70.11% of the companies in the same industry.
  • ADMA has a Quick Ratio of 3.65. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ADMA (3.65) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 7.13
Quick Ratio 3.65
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite good.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%18.38%

3.2 Future

  • ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.09% yearly.
  • ADMA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.52% yearly.
EPS Next Y52.15%
EPS Next 2Y41.03%
EPS Next 3Y42.02%
EPS Next 5Y34.09%
Revenue Next Year24.12%
Revenue Next 2Y22.95%
Revenue Next 3Y24.33%
Revenue Next 5Y19.52%

3.3 Evolution

ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 25.95, which means the current valuation is very expensive for ADMA.
  • Compared to the rest of the industry, the Price/Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 92.53% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.07. ADMA is around the same levels.
  • Based on the Price/Forward Earnings ratio of 17.06, the valuation of ADMA can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 94.64% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. ADMA is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 25.95
Fwd PE 17.06
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 93.87% of the companies in the same industry are more expensive than ADMA, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 91.19% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 91.25
EV/EBITDA 21.24
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ADMA has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ADMA's earnings are expected to grow with 42.02% in the coming years.
PEG (NY)0.5
PEG (5Y)N/A
EPS Next 2Y41.03%
EPS Next 3Y42.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ADMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADMA BIOLOGICS INC

NASDAQ:ADMA (2/27/2026, 8:00:00 PM)

After market: 15.28 -0.29 (-1.86%)

15.57

+0.39 (+2.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners93.5%
Inst Owner Change-2.89%
Ins Owners2.35%
Ins Owner Change3.92%
Market Cap3.71B
Revenue(TTM)N/A
Net Income(TTM)209.45M
Analysts82.22
Price Target26.18 (68.14%)
Short Float %8.5%
Short Ratio8.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)0%
PT rev (3m)-5.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.87%
Valuation
Industry RankSector Rank
PE 25.95
Fwd PE 17.06
P/S 7.58
P/FCF 91.25
P/OCF 57.03
P/B 8.59
P/tB 8.68
EV/EBITDA 21.24
EPS(TTM)0.6
EY3.85%
EPS(NY)0.91
Fwd EY5.86%
FCF(TTM)0.17
FCFY1.1%
OCF(TTM)0.27
OCFY1.75%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)0.5
PEG (5Y)N/A
Graham Number4.95
Profitability
Industry RankSector Rank
ROA 36.83%
ROE 48.57%
ROCE 32.61%
ROIC 25.76%
ROICexc 29.27%
ROICexgc 29.53%
OM 34.19%
PM (TTM) 42.87%
GM 54.71%
FCFM 8.31%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.78
Debt/EBITDA 0.4
Cap/Depr 304.79%
Cap/Sales 4.99%
Interest Coverage 15.23
Cash Conversion 37.13%
Profit Quality 19.39%
Current Ratio 7.13
Quick Ratio 3.65
Altman-Z 18.21
F-Score7
WACC8.6%
ROIC/WACC3
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y52.15%
EPS Next 2Y41.03%
EPS Next 3Y42.02%
EPS Next 5Y34.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%18.38%
Revenue Next Year24.12%
Revenue Next 2Y22.95%
Revenue Next 3Y24.33%
Revenue Next 5Y19.52%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.1%
EBIT Next 3Y45.85%
EBIT Next 5Y36.27%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A

ADMA BIOLOGICS INC / ADMA FAQ

What is the fundamental rating for ADMA stock?

ChartMill assigns a fundamental rating of 7 / 10 to ADMA.


What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?

ChartMill assigns a valuation rating of 7 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Undervalued.


How profitable is ADMA BIOLOGICS INC (ADMA) stock?

ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.


What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?

The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.